Retirement Systems of Alabama Has $15.30 Million Stake in Haemonetics Co. (NYSE:HAE)

Retirement Systems of Alabama boosted its holdings in Haemonetics Co. (NYSE:HAE) by 0.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 178,951 shares of the medical instruments supplier’s stock after purchasing an additional 232 shares during the quarter. Retirement Systems of Alabama’s holdings in Haemonetics were worth $15,302,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. raised its stake in Haemonetics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,380,858 shares of the medical instruments supplier’s stock worth $482,017,000 after purchasing an additional 27,146 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in Haemonetics by 37.0% in the 3rd quarter. Westfield Capital Management Co. LP now owns 559,963 shares of the medical instruments supplier’s stock worth $50,161,000 after purchasing an additional 151,144 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Haemonetics by 6.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 525,793 shares of the medical instruments supplier’s stock valued at $47,101,000 after buying an additional 33,294 shares during the period. Victory Capital Management Inc. increased its holdings in Haemonetics by 50.0% in the 3rd quarter. Victory Capital Management Inc. now owns 357,303 shares of the medical instruments supplier’s stock valued at $32,007,000 after buying an additional 119,072 shares during the period. Finally, Eagle Asset Management Inc. increased its holdings in Haemonetics by 2.6% in the 3rd quarter. Eagle Asset Management Inc. now owns 268,643 shares of the medical instruments supplier’s stock valued at $24,065,000 after buying an additional 6,828 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Trading Up 0.6 %

Shares of Haemonetics stock opened at $92.05 on Wednesday. The firm has a market capitalization of $4.68 billion, a PE ratio of 37.42, a price-to-earnings-growth ratio of 2.16 and a beta of 0.36. The company has a current ratio of 2.92, a quick ratio of 1.76 and a debt-to-equity ratio of 0.91. The firm’s 50 day moving average is $81.20 and its 200 day moving average is $82.60. Haemonetics Co. has a 1 year low of $70.74 and a 1 year high of $95.26.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.10. The company had revenue of $336.20 million for the quarter, compared to analyst estimates of $320.84 million. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The firm’s revenue was up 10.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.85 EPS. Equities research analysts forecast that Haemonetics Co. will post 3.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. TheStreet lowered shares of Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th. Barrington Research reissued an “outperform” rating and issued a $105.00 target price on shares of Haemonetics in a report on Friday, April 12th. Finally, StockNews.com lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.